Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
On Dec 20, 2020, the Israeli Ministry of Health launched a national COVID-19 vaccination campaign that aimed to rapidly vaccinate all high-risk individuals by the end of January, 2021, using the Pfizer BNT162b2 mRNA vaccine.Vaccines were readily available and free of charge. Patients with cancer who have been treated with systemic anticancer therapy are at a significantly increased risk of mortality from COVID-19,and therefore should be considered as a high-priority group for COVID-19 vaccination. Because the pivotal vaccination study for BNT162b2 included only healthy individuals or those with stable chronic medical conditions,a major obstacle faced by the Ministry of Health and by the National Council for the Prevention Diagnosis and Treatment of Malignant Disease was an absence of data regarding the safety and efficacy of the vaccine in patients with cancer who have been or are being treated. Based on available knowledge regarding other routinely used vaccines (eg, the influenza vaccine) the Ministry of Health recommended vaccination of all patients with cancer.However, some experts at the National Council raised concerns regarding the ability of the vaccine to provoke or enhance immune-related side-effects in patients who are being treated with immune checkpoint inhibitors. Thus, the Ministry of Health left the decision about vaccinating individuals treated with immune checkpoint inhibitors to the discretion of their treating physician.
The Lancet Oncology , commentaire en libre accès, 2020